Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Purged Stem Cell Transplant for CML
NCT00446173Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Planned start Mar 2007; status: withdrawn.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00446173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00446173.